Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
AMEUF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.19
+125%
0.97
vs -3.96
Q2.20
N/A
-1.01
vs -1.96
Q4.20
N/A
-1.57
vs 0.97
Q2.21
N/A
-1.58
vs -1.01
Q4.21
N/A
-1.51
vs -1.57
Q2.22
N/A
-1.60
vs -1.58
Q4.22
N/A
-1.60
vs -1.51
Q2.23
N/A
-2.01
vs -1.60
Q4.23
N/A
-2.30
vs -1.60
Q2.24
N/A
-2.75
vs -2.01
Sales Growth
YoY
Current
Estimates
Q4.19
-50%
6.4M vs 12.8M
Q2.20
-63%
3.9M vs 10.7M
Q4.20
-51%
3.1M vs 6.4M
Q2.21
-20%
3.2M vs 3.9M
Q4.21
+48%
4.6M vs 3.1M
Q2.22
-22%
2.5M vs 3.2M
Q4.22
-54%
2.1M vs 4.6M
Q2.23
-5%
2.3M vs 2.5M
Q4.23
-16%
1.8M vs 2.1M
Q2.24
-9%
2.1M vs 2.3M
Return on Equity
QoQ
Q2.21
+261%
2.61
vs -3.87
Q4.21
-87%
-0.87
vs 2.61
Q2.22
-71%
-0.71
vs -0.87
Q4.22
-168%
-1.68
vs -0.71
Q2.23
-143%
-1.43
vs -1.68
Q4.23
-130%
-1.30
vs -1.43
Q2.24
-895%
-8.95
vs -1.30
Q4.24
-66%
-0.66
vs -8.95
Institutionnal Ownership
https://www.proactiveinvestors.com
6 hours ago
globenewswire.com
7 hours ago
businesswire.com
7 hours ago
seekingalpha.com
15 hours ago
businesswire.com
19 hours ago
businesswire.com
22 hours ago
Relative Strength
AMEUF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Anteris Technologies Ltd operates as a structural heart company. It manufactures and sells ADAPT, a regenerative tissue product. The company also engages in the developing of DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. In addition, it researches and develops regenerative medicines. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.
PNK
Unprofitable
Unprofitable
-3.18 ( -35.81%)
Relative Strenght
Volume Buzz
-95%
Earning Acce
No
Dist 52w H.
63%Forecast
47%2025-Revenue
-56%2025-EPS
95%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics